Tables
- Table 1
Summary of results
Medication Incidence Mortality Aspirin No effect No effect Risk reduction of 13–19% for deaths of lung cancer patients when taken ≥1.5 years (aHR# 0.81 and aHR¶ 0.87) Statins No effect Dose-dependent risk reduction of 23% in subjects with cumulative use for ≥1.5 years (aHR#,¶ 0.77) Metformin Reduced for ever-users (aHR¶ 0.89) Reduced risk in diabetic subjects with ≥1.5 years metformin use (aHR¶ 0.76) compared to those who did not take metformin Reduced in subjects with ≥1.5 years of metformin use (aHR¶ 0.44) Triple combination Reduced for ever-users (aHR# 0.83) Reduced for ever-users (aHR# 0.83) Reduced in subjects with ≥1.5 years of combination drug use (aHR# 0.49) Reduced in subjects with ≥1.5 years of combination drug use (aHR# 0.42) aHR: adjusted hazard ratio. #: adjustment for age, sex, income, body mass index, smoking, alcohol comsumption and Charlson comorbidity index; ¶: additional adjustment for other medication use (e.g. aspirin use was adjusted for statin use and metformin use).
Vol 17 Issue 2
Table of Contents
Associations of aspirin, statins and metformin with lung cancer risk and related mortality
